Nov. 15 at 4:34 PM
$CDTX Any thoughts on the deal being an asset purchase? All good and wonderful and how can you not love the
$221.50 cash per share. But if this is an asset purchase the approx. 9 billion will go to the company and not directly to shareholders. I beleive all the preferreds have to paid out first from any BO proceeds before the general shareholders too. Merck in an asset purchase would be buying specific assets and liabilities of CDTX and does not acquire the actual stock of the company. So I'm alittle confused about where we stand with this deal with the information we've been given. They really only mention CD388, or did they say they were buying all the assets? I didn't really read that, anyone? I do seem to recall reading something about tendering shares, but that doesn't happen in an asset sale. There is some independent commentary going around now too, so maybe I picked that up from some of that reading. At the moment does anyone have more clarity here?
